Kundu Shilajit D, Grubb Robert L, Roehl Kimberly A, Antenor Jo Ann V, Han Misop, Catalona William J
Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
J Urol. 2005 Apr;173(4):1116-20. doi: 10.1097/01.ju.0000155460.20581.a4.
The American Urological Association and American Cancer Society advocate annual screening with serum prostate specific antigen (PSA) and digital rectal examination starting at age 50 years in the general population and earlier in men at high risk. Some groups have suggested that screening at 2 or 4-year intervals may be sufficient in men with initial PSA 2 ng/ml or less. We reviewed the records of men enrolled in a PSA and digital rectal examination based prostate cancer screening study to determine the extent to which the diagnosis of cancer would have been delayed using a 2 or 4-year screening interval.
We evaluated 18,140 volunteers in a prostate cancer screening study in whom PSA was less than 2 ng/ml at initial screening and who were screened at 6-month to 1-year intervals for up to 8 years. We evaluated the cancers detected in these intervals to determine the possible delay in cancer diagnosis that would occur using prolonged screening intervals. We report the overall cancer detection rate, clinical and pathological tumor stage, and Gleason grade of the cancers detected.
Excluding 70 men in whom prostate cancer was detected at initial evaluation 2.0% had prostate cancer detected during the next 8 years (mean 21.6 cancers per 6 months, median 20, range 12 to 33). Using a hypothetical 2-year screening interval cancer detection 62% would have been delayed by 4 to 20 months. Using a hypothetical 4-year screening interval cancer detection would have been delayed in 77% of men by 4 to 44 months. Of the tumors detected 100% were clinically localized, 77% were pathologically organ confined and 29% had a Gleason score of 7 or greater.
The 2 or 4-year PSA screening interval in men with initial serum PSA less than 2 ng/ml would result in substantial delays in prostate cancer detection. To our knowledge the extent to which these delays would affect treatment outcomes is undetermined.
美国泌尿外科学会和美国癌症协会提倡在普通人群中从50岁开始每年进行血清前列腺特异性抗原(PSA)检测和直肠指检,高危男性则更早开始。一些团体认为,初始PSA小于等于2 ng/ml的男性,每2年或4年进行一次筛查可能就足够了。我们回顾了一项基于PSA检测和直肠指检的前列腺癌筛查研究中男性参与者的记录,以确定采用2年或4年筛查间隔会在多大程度上延迟癌症诊断。
我们评估了一项前列腺癌筛查研究中的18140名志愿者,这些志愿者在初次筛查时PSA小于2 ng/ml,并且每隔6个月至1年进行一次筛查,最长持续8年。我们评估了在这些时间段内检测到的癌症,以确定采用延长的筛查间隔可能导致的癌症诊断延迟情况。我们报告了总体癌症检出率、临床和病理肿瘤分期以及所检测癌症的Gleason分级。
排除初次评估时就检测出前列腺癌的70名男性,2.0%的男性在接下来的8年中检测出前列腺癌(每6个月平均检出21.6例癌症,中位数为20例,范围为12至33例)。采用假设的2年筛查间隔,62%的癌症检出会延迟4至20个月。采用假设的4年筛查间隔,77%的男性癌症检出会延迟4至44个月。在检测出的肿瘤中,100%为临床局限性肿瘤,77%为病理器官局限性肿瘤,29%的Gleason评分为7分或更高。
初始血清PSA小于2 ng/ml的男性采用2年或4年的PSA筛查间隔会导致前列腺癌检测出现显著延迟。据我们所知,这些延迟对治疗结果的影响程度尚不确定。